secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cryoport, Inc. (CYRX)
CIK:        0001124524
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001104659-25-106421
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cryoport Q3 revenue rises 15% to $44.2M; raises FY2025 guidance to $170-174M
----------------------------------------------------------------------------

- Q3 continuing ops revenue $44.2M (+15% YoY); gross margin 48.2% vs 45.5%.
- Commercial Cell & Gene Therapy revenue up 36% YoY to $8.3M; supported 19 commercial therapies.
- GAAP net loss attributable to common stockholders $8.9M ($0.18 loss per share) in Q3.
- Adjusted EBITDA from continuing ops improved to -$0.6M from -$2.7M; cash/investments $421.3M.
- Full-year 2025 revenue guidance raised to $170M-$174M from continuing operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124524/000110465925106421/0001104659-25-106421-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124524/000110465925106421/tm2530148d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-106421

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer